Clinical Trial Update: The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo

View source ↗

Summary

A completed NIAID-sponsored trial evaluated using the bacteriophage Phi X174 to assess immune competence in HIV-infected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Status: COMPLETED